{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:25:16Z","timestamp":1783988716184,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,19]]},"DOI":"10.7759\/cureus.69704","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T09:56:14Z","timestamp":1726739774000},"source":"Crossref","is-referenced-by-count":7,"title":["Semaglutide-Induced Acute Pancreatitis Leading to Death After Four Years of Use"],"prefix":"10.7759","author":[{"given":"Chebly","family":"Dagher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Jailani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Akiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zidan","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Nadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s005920050116","article-title":"Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective","volume":"35","author":"Nauck MA","year":"1998","unstructured":"Nauck MA. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Acta Diabetol. 1998, 35:117-29. 10.1007\/s005920050116","journal-title":"Acta Diabetol"},{"key":"ref2","article-title":"A new era for glucagon-like peptide-1 receptor agonists (Article in French)","volume":"78","author":"Neuville MF","year":"2023","unstructured":"Neuville MF, Paquot N, Scheen AJ. A new era for glucagon-like peptide-1 receptor agonists (Article in French). Rev Med Liege. 2023, 78:40-5.","journal-title":"Rev Med Liege"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2019-137186","article-title":"An overview of GLP-1 agonists and recent cardiovascular outcomes trials","volume":"96","author":"Sheahan KH","year":"2020","unstructured":"Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad Med J. 2020, 96:156-61. 10.1136\/postgradmedj-2019-137186","journal-title":"Postgrad Med J"},{"key":"ref4","unstructured":"Ozempic\u00ae (semaglutide) is the #1 prescribed GLP-1 RA worldwide in patients with T2D. (2018). Accessed. September 2024: https:\/\/www.novomedlink.com\/diabetes\/products\/treatments\/ozempic.html."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2021-001952","article-title":"Wegovy (semaglutide): a new weight loss drug for chronic weight management","volume":"70","author":"Singh G","year":"2022","unstructured":"Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022, 70:5-13. 10.1136\/jim-2021-001952","journal-title":"J Investig Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide","volume":"12","author":"Smits MM","year":"2021","unstructured":"Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne). 2021, 12:645563. 10.3389\/fendo.2021.645563","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi M","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023, 330:1795-7. 10.1001\/jama.2023.19574","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref9","article-title":"A meta-analysis preliminary result: effectiveness and safety of oral semaglutide vs. injectable semaglutide in weight loss in general population indifferent of diabetic status","volume":"3","author":"Albalushi S","year":"2024","unstructured":"Albalushi S, Tran KN, Talpeka A, et al.. A meta-analysis preliminary result: effectiveness and safety of oral semaglutide vs. injectable semaglutide in weight loss in general population indifferent of diabetic status. TTU J Biomed Sci. 2024, 3:11-22.","journal-title":"TTU J Biomed Sci"},{"key":"ref10","unstructured":"Incorporation of nutrition education with medication injection to sustain weight loss. (2024). Accessed. September 2024: https:\/\/scholar.dominican.edu\/nursing-senior-theses\/147\/."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff M","year":"2011","unstructured":"Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011, 141:150-6. 10.1053\/j.gastro.2011.02.018","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12833","article-title":"Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study","volume":"19","author":"Knapen LM","year":"2017","unstructured":"Knapen LM, de Jong RG, Driessen JH, et al.. Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study. Diabetes Obes Metab. 2017, 19:401-11. 10.1111\/dom.12833","journal-title":"Diabetes Obes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43773","article-title":"Acute pancreatitis in a patient taking semaglutide","volume":"15","author":"Patel F","year":"2023","unstructured":"Patel F, Gan A, Chang K, Vega KJ.  Acute pancreatitis in a patient taking semaglutide. Cureus. 2023, 15:e43773. 10.7759\/cureus.43773","journal-title":"Cureus"},{"key":"ref14","article-title":"Semaglutide associated acute necrotizing pancreatitis: a case report","author":"Araiza A","year":"2024","unstructured":"Araiza A, Alvarez G, Hastrup F. Semaglutide associated acute necrotizing pancreatitis: a case report. Am Thorac Soc. 2024, 5691.","journal-title":"Am Thorac Soc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain M","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al.. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019, 381:841-51. 10.1056\/NEJMoa1901118","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/292818-semaglutide-induced-acute-pancreatitis-leading-to-death-after-four-years-of-use","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T09:56:17Z","timestamp":1726739777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/292818-semaglutide-induced-acute-pancreatitis-leading-to-death-after-four-years-of-use"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.69704","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,19]]}}}